When will DBV.PA stock report earnings and why does it matter?

DBV.PA stock reports on 23 Mar 2026 at 16:30 UTC. The report matters because management updates on Viaskin trials and cash runway can change valuation quickly for this clinical-stage biotech.

What are the key financials to watch in the DBV.PA earnings report?

Watch cash on hand, operating cash flow, R&D expense trajectory, and any guidance on burn. DBV.PA shows **EPS -0.91**, cash per share **€0.73**, and operating cash flow per share **-€1.02**.

What price targets should investors consider for DBV.PA stock?

Meyka AI's 12‑month forecast is **€4.16** (implied +26.29% vs €3.295). A bullish catalyst scenario reaches **€4.90**, while a downside scenario could test **€2.50** if trials or guidance disappoint.

How liquid and volatile is DBV.PA stock for intraday traders?

DBV.PA stock trades with average volume **1,433,796** but current volume is lower at **174,336**, increasing volatility risk. ATR is **€0.23**, RSI **41.21**, so expect swings around news events.

EU Stocks

DBV.PA DBV Technologies EURONEXT earnings intraday: Q4 due 23 Mar 2026, watch Viaskin

ByHuzaifa Zahoor March 23, 2026March 23, 2026

DBV.PA stock trades at €3.30 as investors prepare for DBV Technologies S.A.’s Q4 earnings due 23 Mar 2026 at 16:30 UTC. Expect the report to focus on Viaskin clinical progress and cash runway. Today’s intraday price range is €3.26–€3.35 on volume 174,336, below the 50-day average of €3.68. This earnings spotlight outlines what analysts watch, key ratios, and short-term trade triggers for DBV.PA stock.